Formulation and Evaluation of Apigenin-Loaded Hybrid Nanoparticles

Apigenin (AGN) is a potent phytochemical with strong antioxidant and anticancer potential. But its therapeutic efficacy is limited due to its high lipophilic characteristics. Therefore, the present investigation aimed to develop AGN-loaded polymer-lipid hybrid nanoparticles (AGN-PLHNPs). Herein, we...

Full description

Saved in:
Bibliographic Details
Main Authors: Imran Kazmi (Author), Fahad A. Al-Abbasi (Author), Syed Sarim Imam (Author), Muhammad Afzal (Author), Muhammad Shahid Nadeem (Author), Hisham N. Altayb (Author), Sultan Alshehri (Author)
Format: Book
Published: MDPI AG, 2022-04-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_aca7a8c3d8fe4f18b830269e87b376a0
042 |a dc 
100 1 0 |a Imran Kazmi  |e author 
700 1 0 |a Fahad A. Al-Abbasi  |e author 
700 1 0 |a Syed Sarim Imam  |e author 
700 1 0 |a Muhammad Afzal  |e author 
700 1 0 |a Muhammad Shahid Nadeem  |e author 
700 1 0 |a Hisham N. Altayb  |e author 
700 1 0 |a Sultan Alshehri  |e author 
245 0 0 |a Formulation and Evaluation of Apigenin-Loaded Hybrid Nanoparticles 
260 |b MDPI AG,   |c 2022-04-01T00:00:00Z. 
500 |a 10.3390/pharmaceutics14040783 
500 |a 1999-4923 
520 |a Apigenin (AGN) is a potent phytochemical with strong antioxidant and anticancer potential. But its therapeutic efficacy is limited due to its high lipophilic characteristics. Therefore, the present investigation aimed to develop AGN-loaded polymer-lipid hybrid nanoparticles (AGN-PLHNPs). Herein, we successfully developed AGN-PLHNPs and optimized them by a 33-Box-Behnken de-sign. The poly (lactic-co-glycolic acid) (PLGA; coded as F1), phospholipon 90 G (PL-90G; coded as F2), and poloxamer 188 (P-188; coded as F3) were considered as the independent factors while particle size (PS; coded as R1), entrapment efficiency (%EE; R2), and cumulative drug release (%CDR; R3) were selected as dependent responses. The average PS, %EE, and %CDR of the AGN-PLHNPs were observed in the range of 101.93 nm to 175.26 nm, 58.35% to 81.14%, and 71.21% to 93.31%, respectively. The optimized AGN-PLHNPs revealed better homogeneity (poly-dispersity index < 0.2) and colloidal stability with high zeta potential (>25 mV). It also exhibited fast release in the initial 4 h after that sustained release up to 48 h of study. Moreover, the results of both DPPH as well as ABTS assays revealed significant improvement in the antioxidant activity. Furthermore, the optimized AGN-PLHNPs exhibited enhanced cytotoxicity efficacy against MCF-7 as well as MDA-MB-231 breast cancer cell lines. 
546 |a EN 
690 |a Apigenin 
690 |a breast cancer 
690 |a optimization 
690 |a cytotoxicity study 
690 |a antioxidant activity 
690 |a Pharmacy and materia medica 
690 |a RS1-441 
655 7 |a article  |2 local 
786 0 |n Pharmaceutics, Vol 14, Iss 4, p 783 (2022) 
787 0 |n https://www.mdpi.com/1999-4923/14/4/783 
787 0 |n https://doaj.org/toc/1999-4923 
856 4 1 |u https://doaj.org/article/aca7a8c3d8fe4f18b830269e87b376a0  |z Connect to this object online.